BiOptic Inc. Reports NT$0.76 EPS for 2024, Proposes NT$1.3 Dividend Per Share

Rebound in China Drives Record Q1 Revenue for BiOptic Inc.; Positive Outlook for 2025

BiOptic Inc. (Stock Code: 6850) announced today (April 24) that its Board of Directors has approved the financial report and earnings distribution plan for fiscal year 2024.

For the year 2024, BiOptic Inc. reported consolidated revenue of NT$202 million, representing an 11% year-on-year decrease. Net income attributable to the parent company was NT$22.73 million, down 40% year-on-year, with earnings per share (EPS) of NT$0.76. Despite the decline, the Board has proposed an above-average dividend payout of NT$1.3 per share, including NT$0.3 in cash dividends and NT$1 in stock dividends. Of the stock dividends, NT$0.7 per share will be issued from capital surplus, allowing shareholders to receive tax-exempt distributions, a move aimed at rewarding long-term investor support.

President Eric Tsai stated that China remains BiOptic’s largest sales market. However, last year’s imbalance in China’s economic growth structure dampened domestic consumption and investment confidence. Combined with fiscal pressures at the local government level, this led China to become the only market within BiOptic’s global portfolio to register a decline, ultimately weighing on overall performance. Nevertheless, BiOptic was one of the few players in the industry to remain profitable throughout the year.

In the first quarter of 2025, order momentum from China has shown a clear rebound, while other international markets continue steady growth. March consolidated revenue reached NT$18.01 million, up 25.9% month-on-month and 16.85% year-on-year. This contributed to a record-high Q1 consolidated revenue of NT$50.91 million, up 22.9% year-on-year.

President Tsai noted that domestic demand in China is gradually recovering, supported by favorable policy measures. Signs of broader economic recovery are emerging. Additionally, with Illumina recently added to China’s Ministry of Commerce “Unreliable Entity List,” BiOptic may benefit from potential order shifts. The company is also actively exploring strategic alliances with local partners across the supply chain to build a resilient global network, key drivers for future revenue and market share expansion.

Regarding the recent global economic volatility triggered by reciprocal U.S. tariffs, Tsai emphasized that BiOptic’s business in the U.S. is still in the early stages. In fact, technology transfer to the U.S. began as early as the second half of 2024, insulating operations from immediate impact. The company will continue to closely monitor U.S. trade policy developments and adjust its business strategy accordingly.

Looking ahead to 2025, Tsai remarked that the ongoing U.S.-China trade tensions could drive adoption of BiOptic’s proprietary platforms in regions impacted by U.S. tariff measures. Meanwhile, the company continues expanding its overseas footprint. Beyond successful inroads into Europe and the Middle East, BiOptic recently signed a three-party memorandum of understanding with Hermo Electric Co., Ltd. and GGA Corp., aiming to explore Japan’s precision health and personalized medicine market jointly. This move will deepen BiOptic’s presence in Japan and further diversify its operational risk.

In addition, BiOptic has completed a group-wide internal integration project, significantly reducing hidden costs and improving operational efficiency. With both internal enhancements and external market expansion underway, the company maintains a positive outlook for full-year performance in 2025.